Journal article

A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder

Sehrish Sayed, Nicholas T Van Dam, Sarah R Horn, Marin M Kautz, Michael Parides, Sara Costi, Katherine A Collins, Brian Iacoviello, Dan V Iosifescu, Aleksander A Mathe, Steven M Southwick, Adriana Feder, Dennis S Charney, James W Murrough

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | OXFORD UNIV PRESS | Published : 2018

Abstract

BACKGROUND: Anxiety and trauma-related disorders are among the most prevalent and disabling medical conditions in the United States, and posttraumatic stress disorder in particular exacts a tremendous public health toll. We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder. METHODS: Twenty-six individuals were randomized in a cross-over, single ascending dose study into 1 of 5 cohorts: 1.4 mg (n=3), 2.8 mg (n=6), 4.6 mg (n=5), 6.8 mg (n=6), and 9.6 mg (n=6). Each individual was dosed with neuropeptide Y or placebo on separate treatment days 1 week apart in random order under double-blind con..

View full abstract